108 related articles for article (PubMed ID: 38741506)
1. [Lambert-Eaton Myasthenic Syndrome].
Matsuo H
Brain Nerve; 2024 May; 76(5):630-634. PubMed ID: 38741506
[TBL] [Abstract][Full Text] [Related]
2. [P/Q-type Calcium Channel Antibodies in Lambert-Eaton Myasthenic Syndrome].
Kitanosono H; Shiraishi H; Motomura M
Brain Nerve; 2018 Apr; 70(4):341-355. PubMed ID: 29632282
[TBL] [Abstract][Full Text] [Related]
3. [Autoantibody against the presynaptic P/Q-type voltage-gated calcium channel in Lambert-Eaton myasthenic syndrome].
Sakai W; Nakane S; Matsuo H
Brain Nerve; 2013 Apr; 65(4):441-8. PubMed ID: 23568992
[TBL] [Abstract][Full Text] [Related]
4. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies.
Titulaer MJ; Lang B; Verschuuren JJ
Lancet Neurol; 2011 Dec; 10(12):1098-107. PubMed ID: 22094130
[TBL] [Abstract][Full Text] [Related]
5. [Lambert-Eaton myasthenic syndrome (LEMS)].
Suzuki S
Brain Nerve; 2010 Apr; 62(4):419-26. PubMed ID: 20420183
[TBL] [Abstract][Full Text] [Related]
6. Lambert-Eaton myasthenic syndrome: search for alternative autoimmune targets and possible compensatory mechanisms based on presynaptic calcium homeostasis.
Takamori M
J Neuroimmunol; 2008 Sep; 201-202():145-52. PubMed ID: 18653248
[TBL] [Abstract][Full Text] [Related]
7. Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer.
Schoser B; Eymard B; Datt J; Mantegazza R
J Neurol; 2017 Sep; 264(9):1854-1863. PubMed ID: 28608304
[TBL] [Abstract][Full Text] [Related]
8. Lambert-Eaton myasthenic syndrome - diagnosis, pathogenesis and therapy.
Hülsbrink R; Hashemolhosseini S
Clin Neurophysiol; 2014 Dec; 125(12):2328-36. PubMed ID: 25065299
[TBL] [Abstract][Full Text] [Related]
9. [Lambert-Eaton myasthenic syndrome, an immune pathology of neuromuscular junctions].
Honnorat J
Bull Acad Natl Med; 2014 Feb; 198(2):243-54; discussion 255. PubMed ID: 26263702
[TBL] [Abstract][Full Text] [Related]
10. [Molecular immunology of voltage-gated calcium channel and Lambert-Eaton myasthenic syndrome].
Iwasa K; Komai K; Yasukawa Y; Maruta T; Takamori M
Nihon Rinsho; 1997 Dec; 55(12):3322-30. PubMed ID: 9436458
[TBL] [Abstract][Full Text] [Related]
11. Lambert-Eaton myasthenic syndrome.
Lipka AF; Verschuuren JJGM
Handb Clin Neurol; 2024; 200():307-325. PubMed ID: 38494285
[TBL] [Abstract][Full Text] [Related]
12. [Lambert-Eaton myasthenic syndrome].
Motomura M; Fukuda T
Brain Nerve; 2011 Jul; 63(7):745-54. PubMed ID: 21747145
[TBL] [Abstract][Full Text] [Related]
13. Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome.
Motomura M; Lang B; Johnston I; Palace J; Vincent A; Newsom-Davis J
J Neurol Sci; 1997 Mar; 147(1):35-42. PubMed ID: 9094058
[TBL] [Abstract][Full Text] [Related]
14. Proteasome inhibitors for malignancy-related Lambert-Eaton myasthenic syndrome.
Wang C; Chen S; Feng B; Guan Y
Muscle Nerve; 2014 Mar; 49(3):325-8. PubMed ID: 24464710
[TBL] [Abstract][Full Text] [Related]
15. [Lambert-Eaton myasthenic syndrome: diagnosis and treatment].
Motomura M; Iwanaga H
Clin Calcium; 2001 Nov; 11(11):1468-74. PubMed ID: 15775666
[TBL] [Abstract][Full Text] [Related]
16. Pathogenic autoantibodies in the lambert-eaton myasthenic syndrome.
Lang B; Pinto A; Giovannini F; Newsom-Davis J; Vincent A
Ann N Y Acad Sci; 2003 Sep; 998():187-95. PubMed ID: 14592874
[TBL] [Abstract][Full Text] [Related]
17. [Dosage and specificity of anti-calcium channel antibodies in Lambert-Eaton myasthenic syndrome].
Martin-Moutot N; de Haro L; Seagar M
Rev Neurol (Paris); 2004 May; 160(5 Pt 2):S28-34. PubMed ID: 15269657
[TBL] [Abstract][Full Text] [Related]
18. Lambert-Eaton Myasthenic Syndrome.
Kesner VG; Oh SJ; Dimachkie MM; Barohn RJ
Neurol Clin; 2018 May; 36(2):379-394. PubMed ID: 29655456
[TBL] [Abstract][Full Text] [Related]
19. Lambert-Eaton myasthenic syndrome in childhood.
Kostera-Pruszczyk A; Ryniewicz B; Rowinska-Marcinska K; Dutkiewicz M; Kamińska A
Eur J Paediatr Neurol; 2009 Mar; 13(2):194-6. PubMed ID: 18585938
[TBL] [Abstract][Full Text] [Related]
20. Ca2+ channels as targets of neurological disease: Lambert-Eaton Syndrome and other Ca2+ channelopathies.
Flink MT; Atchison WD
J Bioenerg Biomembr; 2003 Dec; 35(6):697-718. PubMed ID: 15000529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
